Haematococcus pluvialis

Haematococcus pluvialis

Identity and Taxonomy

Haematococcus pluvialis (Chlorophyceae) is a unicellular freshwater microalga with global distribution in many watery habitats and is currently recognized as the richest and most promising source for the commercial production of natural astaxanthin. Its full taxonomic classification places it in the Domain Eukaryota, Kingdom Plantae (Viridiplantae), Phylum Chlorophyta, Class Chlorophyceae, Order Chlamydomonadales, and Family Haematococcaceae.

The organism was first observed in 1802 by Justin Girod-Chantrans, who named it Volvox lacustris. The name Haematococcus was first published by Carl Adolph Agardh. Unambiguous reports of the organism were also published by Auguste Morren and Charles François Antoine Morren in 1841 under the name Disceraea, and independently by Julius von Flotow, who used the name Haematococcus and called his organism Haematococcus pluvialis. The type species of Haematococcus was conserved as Haematococcus pluvialis (thereby preferring Flotow's circumscription over Agardh's); however, the accepted taxonomic name of the type species is Haematococcus lacustris. In current scientific literature, both names — H. pluvialis Flotow and H. lacustris (Girod-Chantrans) Rostafinski — appear; the former remains in widespread commercial and research use.

At the cellular level, H. pluvialis is a unicellular, spherical, green biflagellate oleaginous cell with a diameter of approximately 30 µm. At first, H. pluvialis starts as a free-swimming, green biflagellate microalga with a single pyrenoid-containing chloroplast, then loses its flagella and rounds up to become a non-motile palmella, and finally transitions to the thick-walled aplanospore. Cells transition under sustained unfavorable environmental or laboratory culture conditions — such as nutrient deprivation, high light irradiance, high temperature, and/or high salinity — to a "red encysted phase" characterized by red, enlarged, spherical, non-motile aplanospores (hematocysts). The carotenoid content of hematocysts is notably elevated compared to that of green vegetative cells and is dominated by the red pigment astaxanthin (80–99% of total carotenoids).

Haematococcus is a freshwater alga with a nearly cosmopolitan distribution, found from every continent except Antarctica. Members of this group are a common cause of the pink color found in birdbaths, which is caused by the carotenoid pigment astaxanthin.

Traditional and Historical Use

Haematococcus pluvialis itself has no established record of use in any traditional or indigenous pharmacopoeia. Unlike macroalgae such as spirulina or kelp, which have documented histories of human consumption across multiple cultures, H. pluvialis was not identified and characterised as a discrete organism until the early nineteenth century, and its primary pigment, astaxanthin, was not chemically defined until the twentieth century. Dietary supplements containing Haematococcus astaxanthin have been used for over 15 years as a nutraceutical supplement. Microorganisms have been used in the food, medicinal, cosmetic and energy industries for years, and among them, microalgae have proved to be an invaluable source of beneficial compounds.

Astaxanthin is ubiquitous in nature, especially found in the marine environment as a red-orange pigment common to many aquatic animals such as salmonids, shrimp, and crayfish. It is primarily biosynthesized by microalgae and phytoplankton, accumulating in zooplankton and crustaceans and subsequently in fish, from where it is added to higher levels in the food chain. It is within this ecological context — rather than via deliberate ethnobotanical use — that humans encountered astaxanthin historically, through the consumption of salmon and other seafood. The deliberate cultivation and processing of H. pluvialis for nutraceutical applications is a development of the late twentieth and early twenty-first centuries.

Key Constituents and Chemical Composition

Astaxanthin: Primary Bioactive Compound

Astaxanthin, or (3,3′-dihydroxy-β,β-1-carotene-4,4′-dione), is a secondary carotenoid with a bright blood-red color, which can be synthesized directly by exerting cellular stresses onto H. pluvialis. Astaxanthin has a chemical formula of C₄₀H₅₂O₄ and a molecular weight of 596.86 in geometric cis- and trans-isomers; the latter is thermodynamically more stable than the former.

Among carotenoids, astaxanthin is distinguished by a unique chemical structure — a keto-carotenoid (xanthophyll) bearing hydroxyl and keto functional groups at each end of its polyene chain, which confers exceptional antioxidative efficacy. There are up to 13 conjugated double bonds in the molecule of astaxanthin, with a β-violet ketone ring in the head and tail of each molecule as well as both the hydroxyl and carbonyl groups on the ring. Astaxanthin is a high-value keto-carotenoid synthesized from β-carotene by the introduction of hydroxyl and keto moieties at the 3,3′ and 4,4′ positions of the β-ionone rings. The oxygenated groups make keto-carotenoids relatively more polar, allow esterification, and can lead to a higher antioxidant activity.

Eleven astaxanthin monoesters have been identified in H. pluvialis, accounting for approximately 78.8% of the total astaxanthin pool, and six astaxanthin diesters account for 20.5% of the total, while free astaxanthin represents the smallest fraction at approximately 0.7%. The red phase of the alga is considered the most valuable source of carotenoids, including a high content of astaxanthin, which is mostly present in bound lipid form as monoesters and diesters.

H. pluvialis has the highest reported level of astaxanthin at 4% dry weight (DW). Some sources report accumulation up to 5% DW under optimised stress conditions. Currently, over 95% of the astaxanthin available in the market is produced synthetically, while H. pluvialis-derived natural astaxanthin corresponds to less than 1% of the commercialised quantity.

Other Carotenoids and Bioactive Compounds

Besides astaxanthin, H. pluvialis contains several other carotenoids, the predominant ones being β-carotene, α-carotene, β-cryptoxanthin, lycopene, lutein and violaxanthin, as well as a number of other bioactive compounds such as proteins, lipids and other bioactive substances. In the green vegetative cells, the carotenoid fraction consists mostly of lutein (75–80%), β-carotene (10–20%) and others, including chlorophyll a and b, primary carotenoids, violaxanthin, neoxanthin, lactucaxanthin, and zeaxanthin. Based on dry biomass weight, during the "green phase," up to 1% lutein content is present and total lipid content varies from 20–25%, whereas the "red phase" contains 32–37% lipids and deposits 1–5% of astaxanthin.

Stereochemistry and Natural vs. Synthetic Forms

Conventional racemic synthetic astaxanthin may have limited use since only one-quarter of the compound is the 3S,3′S isomer commonly found in natural salmon and studied in humans for efficacy and safety. Astaxanthin may also be synthesized in a stereospecific manner so that the output is exclusively the generally accepted 3S,3′S isomer in a free diol form. Natural astaxanthin from H. pluvialis is predominantly in the 3S,3′S configuration. The Trolox equivalent antioxidant capacity (TEAC) assay has shown that natural extracts containing astaxanthin esters display stronger antioxidant activities than free astaxanthin.

Commercial Forms and Preparations

Natural astaxanthin from H. pluvialis or krill oil is available in the market as a dietary supplement in dosages from 3.8 to 7.6 mg per day due to potential health benefits. The free diol crystals can be suspended in a vegetable oil or solid beadlet for use in edible preparations or in pill, capsule, or tablet form. Extracts are also formulated as oleoresins and soft-gel capsules, typically dissolved in oil to enhance bioavailability, given astaxanthin's fat-soluble nature. Natural extracts are obtained either by solvent or supercritical extraction methods.

Currently, 95% of astaxanthin available in the market is produced synthetically using petrochemicals due to cost-efficiency for mass production. Safety issues have arisen regarding the use of synthetic astaxanthin for human consumption, while the astaxanthin derived from H. pluvialis is the main source for several human applications, including dietary supplements, cosmetics, and food.

The United States Food and Drug Administration (FDA) has approved the use of astaxanthin as a food colorant in animal and fish feed. The European Commission considers natural astaxanthin as a food dye. In dietary supplement markets, H. pluvialis-derived astaxanthin is sold as capsules, softgels, tablets, and increasingly in topical formulations for cosmetic applications.

Mechanisms of Action

Antioxidant Mechanisms

Astaxanthin stands out from other antioxidants as it has shown the highest oxygen radical absorbance capacity (ORAC), 100–500 times higher than α-tocopherol and a 10-times higher free radical inhibitory activity than related antioxidants (α-tocopherol, α-carotene, β-carotene, lutein and lycopene). The prominent characteristics of the molecular structure determine the powerful and important functions of astaxanthin, such as scavenging free radicals, having antioxidant properties, and quenching the singlet oxygen.

Astaxanthin reduces ROS formation by increasing the expression of oxidative stress-responsive enzymes, such as superoxide dismutase (SOD), glutathione peroxidase (GPx), and catalase (CAT). A structurally important feature is that astaxanthin spans the entire lipid bilayer of cell membranes — with its polar end groups anchoring to both the inner and outer surfaces — unlike β-carotene or vitamin E, which are embedded within one leaflet. This allows it to function as a transmembrane antioxidant chain-breaker.

Anti-inflammatory Mechanisms

Mechanistically, astaxanthin scavenges radicals, triggers the Nrf2-induced activation of the antioxidant system, and suppresses the activation of the NF-κB and mitogen-activated protein kinase pathways. One of the primary mechanisms by which astaxanthin reduces inflammation is through its action on nuclear factor kappa B (NF-κB), a master regulator of pro-inflammatory cytokine production. By down-regulating NF-κB signalling, astaxanthin decreases the expression of inflammatory molecules such as TNF-α, IL-1β, and IL-6.

Astaxanthin also modulates the Nrf2 pathway, which enhances the body's own antioxidant defence system. By activating Nrf2, astaxanthin helps restore redox balance, indirectly dampening inflammation triggered by oxidative stress. Astaxanthin can activate the Nrf2 pathway by promoting the activity of phosphoinositol-3 kinase/protein kinase B (PI3K/Akt) and extracellular signal-regulated protein kinase (ERK) pathways.

In clinical and experimental studies, astaxanthin exhibits its antioxidant and anti-inflammatory actions by reducing the production of cytokines such as IL-1β, IL-6, and TNF-α. Astaxanthin also has the ability to reduce inflammation by inhibiting the cyclooxygenase-1 enzyme (COX-1) and nitric oxide (NO).

Neuroprotective and Barrier Crossing

Astaxanthin modulates neuroinflammation by alleviating oxidative stress, reducing the production of neuroinflammatory factors, inhibiting peripheral inflammation, and maintaining the integrity of the blood-brain barrier. Preclinical and human pharmacokinetic data indicate that astaxanthin can cross the blood–brain barrier, supporting its potential role in neural protection. The ability to cross both the blood–brain barrier and the blood–retinal barrier distinguishes astaxanthin from many carotenoids and is thought to underpin its observed effects on ocular and neurological endpoints.

Skin and Collagen-Related Mechanisms

Astaxanthin has been found to suppress nuclear factor-κB (NF-κB) signalling and collagen degradation proteins, matrix metalloproteinases (MMPs). Mechanistic studies demonstrate that astaxanthin suppresses UV-induced matrix metalloproteinase-1 (MMP-1) expression and inflammatory cytokine release, thereby limiting collagen degradation.

Scientific Evidence by Area of Use

1. Antioxidant and Oxidative Stress Biomarkers

A 2025 systematic review that included fifteen studies involving human participants (excluding in vitro and animal studies) found that astaxanthin consistently reduced pro-inflammatory cytokines (IL-6, TNF-α, TGF-β1) and oxidative stress indices while increasing antioxidant capacity (SOD, TAC). Human trials report reductions in oxidative stress biomarkers such as malondialdehyde and lipid hydroperoxides, alongside increases in endogenous antioxidant defences, including superoxide dismutase. These findings arise across populations including healthy adults, older adults, and patients with metabolic conditions. Overall, the antioxidant evidence in humans is the most consistently positive domain, though most trials are small and short.

2. Skin Health and Photoprotection

Due to its collective diverse functions in skin biology, there is mounting evidence that astaxanthin possesses various health benefits and important nutraceutical applications in the field of dermatology. Although still debated, a range of potential mechanisms through which astaxanthin might exert its benefits on skin homeostasis have been proposed, including photoprotective, antioxidant, and anti-inflammatory effects.

Clinical trials in healthy women have found that astaxanthin supplementation improves the appearance of crow's feet wrinkles, enhances skin elasticity, and reduces water loss through the skin surface. That last effect is notable because it suggests the skin's barrier function improves, not just its cosmetic appearance. Clinical studies show that oral astaxanthin (typically 4–12 mg/day for 8–16 weeks) can reduce UV-induced erythema, improve skin moisture, and support barrier function.

In vitro studies show that H. pluvialis extracts (HPE) and purified astaxanthin (HPA) decrease DNA damage and promote the secretion of collagen from the human normal fibroblast cell line (Hs68) in a dose-dependent manner. The human clinical evidence for skin benefits is preliminary but directionally consistent: multiple small randomised trials support improvements in skin moisture, elasticity, and wrinkle reduction, with the strongest evidence for photoprotection.

3. Eye Health and Visual Function

Benefits on skin and eye health promotion have been reported, highlighting astaxanthin's potential for the prevention of skin photo-aging and the treatment of eye diseases like glaucoma, cataracts and uveitis. A randomised, double-blind trial found that taking 9 mg of astaxanthin daily for six weeks prevented the loss of visual acuity that typically occurs during prolonged screen work. The proposed mechanism involves reduced oxidative stress in the brain and improved blood flow to the small muscles in the eye responsible for focusing. Previous clinical trials have also shown that astaxanthin increases blood flow in the tiny capillaries around the optic nerve.

Animal studies provide supporting mechanistic data: researchers hypothesized that astaxanthin treatment could protect retinal ganglion cells (RGCs) from death via anti-oxidative and anti-apoptotic responses. Adult male Wistar rats were fed astaxanthin (100 mg/kg/day) by daily gavage for seven consecutive days, either before or after inducing oxidative stress in the retina by photodynamic treatment. The visual function, RGC apoptosis, and macrophage infiltration in the optic nerve were investigated. Visual function and RGC densities were significantly higher in both pre- and post-treatment groups, and the numbers of apoptotic RGCs and extrinsic macrophage infiltration in the optic nerve were significantly decreased in both astaxanthin-treated groups. Human clinical evidence for eye health is promising but remains based predominantly on small trials; larger adequately powered randomised controlled trials are lacking.

4. Cardiovascular Health

Astaxanthin, a powerful carotenoid known for its antioxidant and anti-inflammatory properties, has emerged as a promising candidate for preventing and treating cardiovascular disease (CVD). Several studies have shown that astaxanthin can improve cholesterol removal from macrophages, decrease plaque buildup, and enhance lipid profiles by lowering triglycerides and increasing high-density lipoprotein (HDL) cholesterol levels.

Cardiometabolic and respiratory outcomes in human studies have shown improved endothelial function and reduced disease severity. Over the past decade, several reviews have examined the effects of natural astaxanthin on humans, focusing on areas such as antioxidation, liver protection, eye function, skin health, immune response, inflammation, and cardiovascular health. A comprehensive review analysed 87 clinical trials involving over 2,000 participants. While all studies were included to evaluate adverse events and safety concerns, the quality of reporting varied, making comparisons difficult. More recent randomised clinical trials have demonstrated greater scientific rigour than earlier observational studies. Overall, the cardiovascular evidence is directionally positive but remains preliminary; few large, placebo-controlled trials with hard clinical endpoints (e.g., myocardial infarction, stroke) have been published.

5. Exercise Performance and Muscle Recovery

In a randomised controlled trial of young adults, those who took astaxanthin cycled significantly longer before exhaustion: 85 minutes on average compared to 72 minutes in the placebo group, roughly an 18% improvement in endurance. Creatine kinase, a protein that leaks out of damaged muscle fibers after intense exercise, was significantly lower during and immediately after cycling in the astaxanthin group. Lactate dehydrogenase, another marker of muscle cell damage, was also reduced right after exercise.

Combined astaxanthin and exercise interventions have shown improved body composition, lipid profiles, insulin sensitivity, and immune recovery in human studies. The exercise performance literature is composed primarily of small, short-duration trials. While results are encouraging, the magnitude of effect and optimal dosing for specific exercise modalities have not yet been established in large trials.

6. Anti-inflammatory and Immune Function

Astaxanthin demonstrates broad antioxidant and anti-inflammatory properties, supporting its role as a promising adjunctive therapy for metabolic, reproductive, and cardiovascular health. Further well-designed clinical trials are needed to confirm optimal dosing and mechanisms of action. Research suggests that astaxanthin may enhance both cell-mediated and humoral immune responses, including T cell and B cell proliferation, natural killer (NK) cell cytotoxic activity, and IL-6 production. No human studies have yet directly assessed the effect of astaxanthin on Nrf2 and NF-κB transcription factors, although promising clinical trials have demonstrated its potential for the prevention or co-treatment of several human diseases, especially those related to oxidative stress, chronic inflammation, and aging.

7. Neurological and Cognitive Effects

Astaxanthin can protect the nervous system against neurodegenerative diseases such as Alzheimer's and Parkinson's disease. These statements are based primarily on preclinical evidence. Evidence for disease-modifying effects in neurodegenerative disorders remains preliminary, with current support derived mainly from animal models and small human trials. Mounting evidence has revealed that astaxanthin is neuroprotective and has therapeutic potential by inhibiting neuroinflammation; however, its functional roles and underlying mechanisms in modulating neuroinflammation have not been systematically summarised. A growing body of small human studies reports potential benefits on memory and cognitive speed tests, but these require replication in larger, appropriately powered trials before conclusions can be drawn.

8. Metabolic and Reproductive Health

Astaxanthin also protects the liver and helps reduce the risk of chronic kidney disease, and it improves cardiovascular health and has anti-diabetic properties. In clinical human trials, in women with Polycystic Ovary Syndrome (PCOS) or endometriosis, astaxanthin downregulated endoplasmic reticulum stress–related apoptotic pathways and improved oocyte and embryo quality. These findings are from small studies and should be considered early-phase evidence.

Body Systems Associated with Haematococcus pluvialis Use

• Integumentary system (skin): photoprotection, UV-induced erythema reduction, wrinkle improvement, collagen support, barrier function
• Ocular system: retinal protection, visual acuity, digital eye strain, optic nerve blood flow
• Cardiovascular system: lipid profile modulation (triglycerides, HDL), endothelial function, anti-atherogenic potential
• Musculoskeletal system: exercise-induced muscle damage reduction, endurance improvement
• Neurological system: blood-brain barrier integrity, neuroprotection, cognitive function (preliminary)
• Immune system: NK cell activity, lymphocyte proliferation, cytokine modulation
• Metabolic and endocrine system: insulin sensitivity, glycaemic markers, liver protection (largely preclinical)
• Reproductive system: oocyte and embryo quality in PCOS/endometriosis (early clinical evidence)

Dosage Forms and Study Dosages

Most human studies use between 4 and 18 mg of astaxanthin daily, taken for up to 12 weeks. A randomised, double-blind trial on digital eye strain used 9 mg of astaxanthin daily for six weeks. Studies investigating skin and photoprotection outcomes have typically used oral astaxanthin at 4–12 mg/day for 8–16 weeks.

Eight studies investigated the safety of higher doses of astaxanthin, ranging from 8 to 45 mg per day for 4 to 12 weeks. Natural astaxanthin from H. pluvialis or krill oil is available in the market as a dietary supplement in dosages from 3.8 to 7.6 mg per day due to potential health benefits.

Astaxanthin is fat-soluble; bioavailability is enhanced when taken with dietary fat. After consuming a dose of 40 mg astaxanthin as a lipid-based formulation, the plasma concentration increased to approximately 190 µg/L compared to subjects without supplementation. Dosage forms in clinical use include softgel capsules with an oil base, oleoresin preparations, and beadlet powders incorporated into hard-shell capsules or tablets.

Safety, Toxicology, and Regulatory Status

General Tolerability

Clinical studies involving more than 2,000 participants report good tolerability at supplemental doses of 4–12 mg/day for periods up to one year, with no serious adverse effects observed. Most adverse events reported have been mild and gastrointestinal in nature, though formal causality assessments vary. Skin carotenemia — a harmless condition of skin pigmentation — has been observed with high supplemental intake.

EFSA Assessment

In 2014, the EFSA NDA Panel assessed the safety of the Novel Food astaxanthin-rich ingredient derived from microalgae Haematococcus pluvialis in the context of an application submitted under Regulation (EC) No 258/1997. In their reassessment of the toxicological profile of astaxanthin, the EFSA FEEDAP Panel confirmed that astaxanthin was neither mutagenic nor carcinogenic and established an ADI of 0.2 mg astaxanthin/kg body weight per day by applying an uncertainty factor of 200 to a lowest observed adverse effect level (LOAEL) of 40 mg/kg body weight per day for the increased incidence of multinucleated hepatocytes observed in a 2-year carcinogenicity study in rats. The FEEDAP Panel repealed the earlier ADI of 0.034 mg/kg bw established in 2014.

The EFSA considers the combined intake of up to 8 mg/day of astaxanthin from diet and supplements to be safe for adults, corresponding to an acceptable daily intake of 0.2 mg/kg body weight. Available data do not indicate safety concerns for healthy adults; however, evidence is insufficient for pregnancy, lactation, and pediatric use.

FDA Regulatory Status

The FDA has not granted astaxanthin Generally Recognized as Safe (GRAS) status for use as a food additive in the United States, meaning it does not have established safety consensus for food use. However, astaxanthin derived from certain natural sources, particularly the microalga Haematococcus pluvialis, has been approved in some regions. The United States FDA has approved the use of astaxanthin as a food colorant in animal and fish feed.

Drug Interactions and Special Populations

Caution is advised for individuals using antihypertensive, anticoagulant, or antidiabetic medications due to potential additive physiological effects. These interaction signals arise from astaxanthin's effects on blood pressure, platelet function, and glucose metabolism observed in human studies — effects that, while often desirable, may become clinically significant when combined with pharmacological agents acting through the same pathways.

Long-term safety data in food applications remain limited compared to synthetic colorants that have been in use for decades. The evidence base for safety in special populations — including pregnant and lactating women, children, and individuals with chronic liver or kidney disease — remains insufficient, and studies specifically designed to address these groups are lacking.

Natural vs. Synthetic Astaxanthin

Currently 95% of astaxanthin available in the market is produced synthetically using petrochemicals due to cost-efficiency for mass production. Safety issues have arisen regarding the use of synthetic astaxanthin for human consumption, while the astaxanthin derived from H. pluvialis is the main source for several human applications, including dietary supplements, cosmetics, and food. The intracellular antioxidant activity in natural extracts from H. pluvialis has been measured at approximately 90 times higher than synthetic astaxanthin at 5 µM. These differences are attributed both to the predominance of esterified forms in the natural extract and to the stereochemical purity of the 3S,3′S configuration.

Evidence Quality and Research Limitations

The broader body of astaxanthin research — most of which uses H. pluvialis-derived material — must be evaluated critically. A substantial proportion of mechanistic data derives from in vitro cell models and animal studies, which are well-controlled but may not translate directly to human outcomes at nutritional doses. Human clinical trials, while numbering in the dozens, are typically small (often fewer than 50 participants per arm), short in duration (4–12 weeks), and heterogeneous in outcome measures, dosing protocols, and formulations. Further well-designed clinical trials are needed to confirm optimal dosing and mechanisms of action. The quality of reporting in earlier observational studies varied, making comparisons difficult; more recent randomised clinical trials have demonstrated greater scientific rigour. Until adequately powered, long-term Phase III-equivalent randomised controlled trials are conducted in specific disease populations, the clinical evidence for most indications should be considered promising but not conclusive.

References

• Mota GCP et al. "Astaxanthin from Haematococcus pluvialis: processes, applications, and market." Prep Biochem Biotechnol. 2022. PubMed PMID: 34424829
• Haematococcus pluvialis as a Potential Source of Astaxanthin with Diverse Applications in Industrial Sectors: Current Research and Future Directions. PMC8587866
• Oslan SNH et al. "A Review on Haematococcus pluvialis Bioprocess Optimization of Green and Red Stage Culture Conditions for the Production of Natural Astaxanthin." Biomolecules. 2021. PMC7916564
• Mularczyk M et al. "Astaxanthin and other Nutrients from Haematococcus pluvialis—Multifunctional Applications." Mar Drugs. 2020. PMC7551667
• Régnier P et al. "Astaxanthin from Haematococcus pluvialis Prevents Oxidative Stress on Human Endothelial Cells without Toxicity." Mar Drugs. 2015. PMC4446609
• Shah MMR et al. "Astaxanthin-Producing Green Microalga Haematococcus pluvialis: From Single Cell to High Value Commercial Products." Front Plant Sci. 2016. PMC4848535
• Ambati RR et al. "Astaxanthin: Sources, Extraction, Stability, Biological Activities and Its Commercial Applications—A Review." Mar Drugs. 2014. PMC3917265
• Davinelli S et al. "Therapeutic uses of natural astaxanthin: An evidence-based review focused on human clinical trials." Pharmacol Res. 2021. PubMed PMID: 33549728
• The Role of Astaxanthin as an Antioxidant and Anti-Inflammatory Agent in Human Health: A Systematic Review. PMC12840775
• Astaxanthin: A Compound in the Prevention of Chronic Diseases and as a Potential Adjuvant Treatment Agent. PMC12189495
• Davinelli S et al. "Astaxanthin in Skin Health, Repair, and Disease: A Comprehensive Review." Nutrients. 2018. PMC5946307
• Purified Astaxanthin from Haematococcus pluvialis Promotes Tissue Regeneration by Reducing Oxidative Stress and the Secretion of Collagen In Vitro and In Vivo. PMC7424503
• Identification and Content of Astaxanthin and Its Esters from Microalgae Haematococcus pluvialis by HPLC-DAD and LC-QTOF-MS. PMC8625947
• Chemical Transformation of Astaxanthin from Haematococcus pluvialis Improves Its Antioxidative and Anti-inflammatory Activities. PMC7408224
• The Putative Role of Astaxanthin in Neuroinflammation Modulation: Mechanisms and Therapeutic Potential. Front Pharmacol. 2022. PMC9263351
• Davinelli S et al. "Astaxanthin as a Modulator of Nrf2, NF-κB, and Their Crosstalk: Molecular Mechanisms and Possible Clinical Applications." Molecules. 2022. PMC8779084
• Haematococcus pluvialis-Derived Astaxanthin Is a Potential Neuroprotective Agent against Optic Nerve Ischemia. PMC7074344
• The Role of Astaxanthin as a Nutraceutical in Health and Age-Related Conditions. PMC9655540
• EFSA Panel (NDA). "Safety of astaxanthin for its use as a novel food in food supplements." EFSA Journal. 2020.
• Safety of astaxanthin for its use as a novel food in food supplements (PMC version). PMC7448075
• Enriched Astaxanthin Extract from Haematococcus pluvialis Augments Growth Factor Secretions to Increase Cell Proliferation and Induces MMP1 Degradation to Enhance Collagen Production in Human Dermal Fibroblasts. PMC4926488
• Astaxanthin: A promising nutraceutical for cardiovascular health. Journal of King Saud University – Science. 2025.
• AlgaeBase: Haematococcus pluvialis Flotow. Taxonomic record.
• Wikipedia: Haematococcus (taxonomic history section).
• News-Medical.net: Astaxanthin and Human Health: Evidence on Skin, Vision, Brain, and Aging. 2026.